ABCL Q1 2021 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$203M+4253.5% YoY

Gross Profit

$183M90.1% margin

Operating Income

$158M78.0% margin

Net Income

$117M57.8% margin

EPS (Diluted)

$0.37

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

$110M

Free Cash Flow

$106M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$171M

Stockholders' Equity

$957M

Cash & Equivalents

$686M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$203M	$5M	+4253.5%
Gross Profit	$183M	$5M	+3823.8%
Operating Income	$158M	-$2M	+7549.3%
Net Income	$117M	-$2M	+5700.6%

Revenue Segments

Royalty

$171M85%

License

$20M10%

Milestone Payments

$7M3%

Research Fees

$4M2%